Ad hoc:Biofrontera AG:Ad hoc: Biofrontera AG decides on capital increase
(Thomson Reuters ONE) -
Biofrontera AG / / Ad hoc: Biofrontera AG decides on capital increase processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany, August 4, 2010 - Biofrontera has today decided to increase
its base capital by up to 3,590,194.00 EUR through issuing up to 3,590,194 new
shares from authorized capital (New Shares).
Shareholders will be offered the purchase right for 3,590,194 new shares. Lang &
Schwarz Broker GmbH, Breite Straße 34, D-40213 Düsseldorf, has been selected to
take over the shares for 1.00 EUR, with the obligation to transfer them to the
shareholders, respectively the owners of purchase rights, in a 5:2 relation at a
purchase price of 2.20 EUR per share.
The subscription period will begin on August 16, 2010 and close on August
31, 2010. Purchase rights will accordingly be registered depending on the stock
ownings after completion of August 13, 2010. No public trading of purchase
rights is foreseen.
If not all shares will be placed through the purchase offer, Lang & Schwarz
Broker GmbH will offer the remaining shares at the same purchase price to
shareholders who have already exercised their purchase rights. Consequently, all
shareholders who exercised their purchase options of 2 New shares per 5 shares
are eligible to subscribe to shares on top of their legal purchase right by
submitting a binding order. Thus, the additional subscription requires the
purchase of at least two shares from purchase rights.
Shares not drawn by the holders of purchase rights will not be issued within a
private placement. All shares will exclusively be offered and granted to
existing shareholders according to their purchase rights or through an over
purchase.
Further details of the purchase offer will be communicated in the electronic
Federal Bulletin on August 6, 2010.
The proceeds of the capital increase will be used for Biofrontera's operation.
According to the current financial forecast the proceeds will secure the
financing of the Company up to the end of 2011, by which time it is anticipated
that its leading pharmaceutical compound BF-200 ALA for the treatment of actinic
keratosis will have obtained European approval and will be launched in the first
markets.
This ad-hoc release contains forward looking statements that are based on the
current assumptions and prognoses of Biofrontera's management. Known and unknown
risks, uncertainties and other factors may cause the actual development,
particularly approval processes of new drugs, results, the financial development
and the business of the company to differ greatly from the current forward
looking assumptions.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, Germany
ISIN: DE0006046113, WKN: 604611
Contact:
Anke zur Mühlen
Biofrontera AG
Tel.: +49 (0214) 87 63 222
Fax.: +49 (0214) 87 63 290
E-mail:a.zurmuehlen(at)biofrontera.com
[HUG#1435870]
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Börse Düsseldorf;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Biofrontera AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 04.08.2010 - 17:24 Uhr
Sprache: Deutsch
News-ID 38680
Anzahl Zeichen: 0
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 144 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc:Biofrontera AG:Ad hoc: Biofrontera AG decides on capital increase"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
